1932

Abstract

Selective, nonpeptide antagonists for tachykinin receptors first became available ten years ago. Of the three known tachykinin receptors, drug development has focused most intensively on the substance P-preferring receptor, neurokinin (NK). Although originally studied as potential analgesic compounds, recent evidence suggests that NK receptor antagonists may possess antidepressant and anxiolytic properties. If confirmed by further controlled clinical studies, this will represent a mechanism of action distinct from all existing antidepressant agents. As reviewed in this chapter, the existing preclinical and clinical literature is suggestive of, but not conclusive, concerning a role of substance P and NK receptors in the pathophysiology of depression and/or anxiety disorders. The ongoing clinical trials with NK receptor antagonists have served as an impetus for much needed, basic research in this field.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.pharmtox.41.1.877
2001-04-01
2024-04-16
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.pharmtox.41.1.877
Loading
/content/journals/10.1146/annurev.pharmtox.41.1.877
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error